High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib

NARecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
OTHER

60% Oxygen

While participants are exercising, they will be inhaling 60% oxygen through a mask

OTHER

Standard of Care

While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.

Trial Locations (8)

T3M1M4

COMPLETED

University of Calgary, Calgary

T6G 2R3

RECRUITING

University of Alberta, Edmonton

V1V 1V7

COMPLETED

UBC Okanagan, Kelowna

V6Z1Y6

RECRUITING

St. Paul's Hospital, Vancouver

L8S 4L8

RECRUITING

McMaster University, Hamilton

K7L 3N6

COMPLETED

Queens University, Kingston

H3A 0G4

COMPLETED

McGill University, Montreal

G1V 0A6

COMPLETED

Laval University, Québec

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

University of British Columbia

OTHER